| scholarly article | Q13442814 |
| P2093 | author name string | Joseph Finkelstein | |
| Frederick Zhang | |||
| P2860 | cites work | Cytochrome P450 2C19 genetic polymorphisms in Ugandans | Q46496567 |
| Establishment of a biobank and pharmacogenetics database of African populations. | Q46573709 | ||
| Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population | Q46605128 | ||
| CYP2D6 and CYP2C19 genotyping in psychiatric patients on psychotropic medication in the former Dutch Antilles | Q46828988 | ||
| S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians | Q46889792 | ||
| Elevated male European and female African contributions to the genomes of African American individuals | Q46899346 | ||
| Genetic ancestry and indigenous heritage in a Native American descendant community in Bermuda | Q46978264 | ||
| Genetic Polymorphisms of Cytochrome P450 Enzymes and Transport Proteins in a Russian Population and Three Ethnic Groups of Dagestan. | Q47663718 | ||
| Genetic polymorphisms of CYP2C9, CYP2C19, and CYP3A5 in Kosovar population | Q49612685 | ||
| Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review. | Q49733211 | ||
| The CYP2D6 gene locus in South African Coloureds: unique allele distributions, novel alleles and gene arrangements. | Q51966922 | ||
| Switching from prasugrel to clopidogrel based on Cytochrome P450 2C19 genotyping in East Asian patients stabilized after acute myocardial infarction. | Q52903362 | ||
| Race and ethnicity in genetic research. | Q53693804 | ||
| Influence of genetic and non-genetic factors on phenytoin-induced severe cutaneous adverse drug reactions. | Q53782592 | ||
| Genetic polymorphisms of drug-metabolizing phase I enzymes CYP3A4, CYP2C9, CYP2C19 and CYP2D6 in Han, Uighur, Hui and Mongolian Chinese populations. | Q54296906 | ||
| Genetic structure of pharmacogenetic biomarkers in Brazil inferred from a systematic review and population-based cohorts: a RIBEF/EPIGEN-Brazil initiative | Q56382429 | ||
| Race, Ancestry, and Reporting in Medical Journals | Q57458826 | ||
| CYP2C19 activity comparison between Swedes and Koreans: effect of genotype, sex, oral contraceptive use, and smoking | Q58003104 | ||
| Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles | Q58003139 | ||
| Influence of ethnicity on pharmacogenetic variation in the ghanaian population | Q58273618 | ||
| Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations | Q60705807 | ||
| Allele frequency of CYP2C19 in a Portuguese population | Q73691834 | ||
| Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese | Q74380577 | ||
| Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population | Q80626271 | ||
| Racializing drug design: implications of pharmacogenomics for health disparities | Q81418818 | ||
| Does the southern European cardiovascular mortality advantage extend to total mortality? 50-year trends in death risks between 40 and 70 years of age in Western European men and women | Q82381714 | ||
| Genetic polymorphisms of cytochrome P450 enzymes 2C9 and 2C19 in a healthy Mongolian population in China | Q85037693 | ||
| The Implication of the Polymorphisms of COX-1, UGT1A6, and CYP2C9 among Cardiovascular Disease (CVD) Patients Treated with Aspirin | Q86588016 | ||
| Towards Pharmacogenomics-Driven Medication Risk Assessment in People with Polypharmacy | Q95522935 | ||
| Analysis of East Asia genetic substructure using genome-wide SNP arrays | Q21562489 | ||
| Categorization of humans in biomedical research: genes, race and disease | Q21999793 | ||
| The genetic structure and history of Africans and African Americans | Q22065887 | ||
| The use of racial, ethnic, and ancestral categories in human genetics research | Q22066114 | ||
| Population genetic structure of variable drug response | Q22122041 | ||
| Pharmacogenetics, pharmacogenomics, and individualized medicine | Q23919667 | ||
| Genetic structure, self-identified race/ethnicity, and confounding in case-control association studies | Q24530649 | ||
| Different differences: the use of 'genetic ancestry' versus race in biomedical human genetic research | Q24604314 | ||
| Pharmacogenomics knowledge for personalized medicine | Q24623166 | ||
| CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network | Q24632735 | ||
| A global reference for human genetic variation | Q25909434 | ||
| Medical genetics: a marker for Stevens-Johnson syndrome | Q28254047 | ||
| Combination of isosorbide dinitrate and hydralazine in blacks with heart failure | Q28292266 | ||
| Analysis of Genetic Variation in CYP450 Genes for Clinical Implementation | Q28468449 | ||
| Detection of CYP2C19 Genetic Variants in Malaysian Orang Asli from Massively Parallel Sequencing Data | Q28553076 | ||
| A European Spectrum of Pharmacogenomic Biomarkers: Implications for Clinical Pharmacogenomics | Q28554199 | ||
| Genetic diversity of variants involved in drug response and metabolism in Sri Lankan populations: implications for clinical implementation of pharmacogenomics | Q28601852 | ||
| Self-reported race/ethnicity in the age of genomic research: its potential impact on understanding health disparities | Q28651487 | ||
| Human origins. The molecular perspective | Q28730565 | ||
| African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping | Q28748891 | ||
| Is research into ethnicity and health racist, unsound, or important science? | Q28756356 | ||
| Prostate Cancer Genetics: Variation by Race, Ethnicity, and Geography | Q30240027 | ||
| Glossary of terms relating to ethnicity and race: for reflection and debate | Q30478562 | ||
| Characterisation of CYP2C8, CYP2C9 and CYP2C19 polymorphisms in a Ghanaian population | Q30939373 | ||
| Racial categories in medical practice: how useful are they? | Q33300410 | ||
| The World Bank and world health: focus on South Asia-I: Bangladesh | Q33443480 | ||
| Clustering by genetic ancestry using genome-wide SNP data | Q33767014 | ||
| Perceived challenges to public health in Central and Eastern Europe: a qualitative analysis | Q34248467 | ||
| Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future | Q34310938 | ||
| Pharmacogenetics in clinical practice: how far have we come and where are we going? | Q34343365 | ||
| Race as biology is fiction, racism as a social problem is real: Anthropological and historical perspectives on the social construction of race | Q34383100 | ||
| Unravelling the hidden ancestry of American admixed populations | Q34468412 | ||
| Introduction of the AmpliChip CYP450 Test to a South African cohort: a platform comparative prospective cohort study | Q34565428 | ||
| Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. | Q34598487 | ||
| A genomewide admixture map for Latino populations | Q34628377 | ||
| Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population | Q34706677 | ||
| Genetic susceptibility to prostate cancer in men of African descent: implications for global disparities in incidence and outcomes | Q34722941 | ||
| Physicians' attitudes toward race, genetics, and clinical medicine | Q34725511 | ||
| Pharmacogenomics: the genetics of variable drug responses | Q34976915 | ||
| How have the Eastern European countries of the former Warsaw Pact developed since 1990? A bibliometric study | Q34996755 | ||
| Genes, race and research ethics: who's minding the store? | Q35185380 | ||
| A review and assessment of potential sources of ethnic differences in drug responsiveness | Q35217493 | ||
| Prevalence of the CYP2D6*10 (C100T), *4 (G1846A), and *14 (G1758A) alleles among Iranians of different ethnicities | Q35617663 | ||
| A genomewide admixture mapping panel for Hispanic/Latino populations. | Q35788553 | ||
| Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population | Q35803786 | ||
| Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations | Q35825569 | ||
| Race influences warfarin dose changes associated with genetic factors. | Q35884265 | ||
| Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. | Q36053715 | ||
| Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population. | Q36054252 | ||
| Interethnic differences in genetic polymorphisms of CYP2D6 in the U.S. population: clinical implications | Q36395914 | ||
| The ambiguous meanings of the racial/ethnic categories routinely used in human genetics research | Q36405442 | ||
| Allele and genotype frequencies of CYP2B6 and CYP2C19 polymorphisms in Egyptian agricultural workers | Q36406247 | ||
| Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy | Q36441493 | ||
| Genetic Diversity and Association Studies in US Hispanic/Latino Populations: Applications in the Hispanic Community Health Study/Study of Latinos | Q36473454 | ||
| Novel variants of major drug-metabolising enzyme genes in diverse African populations and their predicted functional effects | Q36475190 | ||
| Effect of single nucleotide polymorphisms in cytochrome P450 isoenzyme and N-acetyltransferase 2 genes on the metabolism of artemisinin-based combination therapies in malaria patients from Cambodia and Tanzania | Q36558437 | ||
| Interindividual variability of CYP2C19-catalyzed drug metabolism due to differences in gene diplotypes and cytochrome P450 oxidoreductase content | Q36643041 | ||
| A critical analysis of barriers to the clinical implementation of pharmacogenomics | Q36645801 | ||
| Case-control admixture mapping in Latino populations enriches for known asthma-associated genes | Q36670867 | ||
| Prevalence of major cardiovascular risk factors and cardiovascular diseases among Hispanic/Latino individuals of diverse backgrounds in the United States | Q37182977 | ||
| Ethnic differences in cardiovascular drug response: potential contribution of pharmacogenetics | Q37276490 | ||
| Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study | Q37354223 | ||
| Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine | Q37600573 | ||
| Genetic bio-ancestry and social construction of racial classification in social surveys in the contemporary United States | Q37633644 | ||
| Cytochrome P450 2C9-CYP2C9. | Q37691210 | ||
| African Genetic Diversity: Implications for Cytochrome P450-mediated Drug Metabolism and Drug Development | Q37714285 | ||
| Race, ethnicity, ancestry, and pharmacogenetics | Q37716723 | ||
| Comparison of CYP2C9, CYP2C19, CYP2D6, ABCB1, and SLCO1B1 gene-polymorphism frequency in Russian and Nanai populations. | Q37745681 | ||
| Racial/ethnic differences in drug disposition and response: review of recently approved drugs | Q38351175 | ||
| Policy responses to HIV/AIDS in Central Asia | Q38550264 | ||
| Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations. | Q38616806 | ||
| Exploring public genomics data for population pharmacogenomics | Q38644432 | ||
| Harnessing Knowledge on Very Important Pharmacogenes CYP2C9 and CYP2C19 Variation for Precision Medicine in Resource-Limited Global Conflict Zones | Q38812823 | ||
| Pharmacogenomics of Rosuvastatin: A Glocal (Global+Local) African Perspective and Expert Review on a Statin Drug | Q38955015 | ||
| DNA sensors to assess the effect of VKORC1 and CYP2C9 gene polymorphisms on warfarin dose requirement in Chinese patients with atrial fibrillation | Q39022910 | ||
| Ethnic differences in CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) genotypes in Japanese and Israeli populations | Q39194380 | ||
| Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P450 2C19) in a Shona population of Zimbabwe | Q39222197 | ||
| Comparison of genetic variation in drug ADME-related genes in Thais with Caucasian, African and Asian HapMap populations. | Q40480835 | ||
| Allele and genotype frequencies of CYP2C9, CYP2C19 and CYP2D6 in an Italian population. | Q40506352 | ||
| Potential utility of precision medicine for older adults with polypharmacy: a case series study | Q40655628 | ||
| Distribution of CYP2C19 polymorphisms in Mongolian and Han nationals and the choice of specific antiplatelet drugs | Q41223244 | ||
| Will Precision Medicine Move Us beyond Race? | Q41666847 | ||
| Evaluation of the effects of VKORC1 polymorphisms and haplotypes, CYP2C9 genotypes, and clinical factors on warfarin response in Sudanese patients | Q42734047 | ||
| Elucidation of CYP2D6 genetic diversity in a unique African population: implications for the future application of pharmacogenetics in the Xhosa population | Q43479196 | ||
| CYP2D6 phenotypes among Malays in Malaysia | Q43766125 | ||
| The prevalence of CYP2D6 and CYP2C19 genotypes in a population of healthy Dutch volunteers | Q43877652 | ||
| Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity | Q43879115 | ||
| CYP2C8 polymorphism frequencies among malaria patients in Zanzibar. | Q43948094 | ||
| Genetic polymorphism of CYP2D6 and CYP2C19 in east- and southern African populations including psychiatric patients | Q43951024 | ||
| Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype | Q43952641 | ||
| Evidence for environmental influence on CYP2D6-catalysed debrisoquine hydroxylation as demonstrated by phenotyping and genotyping of Ethiopians living in Ethiopia or in Sweden | Q44079853 | ||
| Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations | Q44486357 | ||
| Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study | Q44803685 | ||
| Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study | Q45337067 | ||
| Personalized medicine and Hispanic health: improving health outcomes and reducing health disparities - a National Heart, Lung, and Blood Institute workshop report. | Q45962241 | ||
| Pharmacogenomics, ethnicity, and susceptibility genes | Q46227252 | ||
| Ancestral proportions and admixture dynamics in geographically defined African Americans living in South Carolina | Q46326944 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 107-123 | |
| P577 | publication date | 2019-07-02 | |
| P1433 | published in | Pharmacogenomics and Personalized Medicine | Q15817568 |
| P1476 | title | Inconsistency in race and ethnic classification in pharmacogenetics studies and its potential clinical implications | |
| P478 | volume | 12 |
| Q96820743 | PharmVar GeneFocus: CYP2C19 |
| Q90208070 | PharmVar GeneFocus: CYP2D6 |
| Q89890370 | Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications |
| Q94544622 | The Identification of Admixture Patterns Could Refine Pharmacogenetic Counseling: Analysis of a Population-Based Sample in Mexico |
Search more.